DR. DONALD DURAND DIVERIO JR., D.O.

Plain English
This study looked at a specific type of leukemia called acute myeloid leukemia (AML) and focused on a genetic mutation known as FLT3 internal tandem duplication (FLT3-ITD). Researchers found that the CD99 protein was present in 100% of patients with FLT3-ITD-AML, whereas it was found in only 48% of those without this mutation. This is important because detecting CD99 can help doctors accurately diagnose FLT3-ITD-AML, which is linked to worse outcomes, and its absence can almost confirm that the mutation is not present. Who this helps: Patients with acute myeloid leukemia and their doctors.

Plain English
This study looked at how well patients with chronic phase chronic myeloid leukemia (CP-CML) can remain free of treatment after stopping their medication for at least three years. Out of 118 patients, about 29% experienced a relapse in their condition after stopping treatment, but 80% were relapse-free after six months. Factors like a high-risk score before treatment and the length of time in a stable response helped predict who was more likely to relapse. Who this helps: This research helps doctors identify which CP-CML patients can safely stop taking medication.

Plain English
This study looked at how 140 patients with FLT3-mutated acute myeloid leukemia (AML) were treated over 24 years. It found that 64% of patients achieved complete remission, with higher success rates in those with an NPM1 mutation (73%). The research highlights that while stem cell transplants are important for treatment, especially allogeneic transplants, there is a need to better understand which patients will gain the most benefit from these procedures. Who this helps: This helps patients with FLT3-mutated AML and their doctors in making informed treatment decisions.

Plain English
This study looked at 220 patients with acute promyelocytic leukemia (APL) to see how different treatment methods affected their survival and recovery from the disease over time. It found that most patients responded well to treatment, with a 3-year survival rate of 80.8% and a 5-year survival rate of 79.1%. Specifically, patients who received certain comprehensive treatments had much higher survival rates, with some groups achieving up to 100% survival within five years. This research is important because it helps doctors better understand which treatments work best and highlights the need for continued research to improve patient outcomes. Who this helps: This helps patients with acute promyelocytic leukemia and their doctors.

Plain English
This study focused on myeloid sarcoma, a rare form of cancer affecting both adults and children, by examining 13 patients treated at a single medical center over 18 years. The researchers analyzed various treatment methods and found that the outcomes vary significantly, highlighting the need for tailored approaches. They emphasized that understanding the best treatments could improve patient care, especially since current methods are not clearly defined. Who this helps: This helps patients with myeloid sarcoma and their doctors by providing insights into better treatment strategies.

Plain English
This study looked at the effectiveness of a treatment called autologous stem cell transplantation (ASCT) for patients with a type of leukemia called favorable-risk acute myeloid leukemia (FR-AML) who were in their first complete remission. Researchers followed 117 patients treated with ASCT over many years and found that 75% of them survived overall, and 76% stayed free of the disease. The study highlighted that certain genetic factors in leukemia affect survival rates and that ASCT is a safe and effective treatment, even for patients with detectable disease before the transplant. Who this helps: This benefits patients with favorable-risk acute myeloid leukemia, as well as their doctors in deciding treatment options.

Plain English
This study looked at how a new method called digital droplet PCR (dPCR) might help doctors determine if patients with chronic myeloid leukemia (CML) can safely stop taking their medication. Researchers found that this method is more sensitive and precise than the traditional testing methods, allowing for better monitoring of remaining disease levels in patients who have stopped treatment. This is important because it could lead to more successful treatment-free periods for patients, allowing them to live healthier lives without continuous medication. Who this helps: Patients with chronic myeloid leukemia seeking to discontinue their treatment safely.

Plain English
Researchers compared two medications, nilotinib and dasatinib, given to patients with chronic myeloid leukemia who did not respond to initial treatment. They studied 131 patients and found that after seven years, about 79% of all patients were still alive, with similar survival rates for both medications: 72% for dasatinib and 86% for nilotinib. Both drugs showed good effectiveness, with patients having substantial chances of significant molecular responses, but more severe side effects were reported with dasatinib. Who this helps: This study benefits patients with chronic myeloid leukemia and their doctors by providing insights into treatment options after initial therapy fails.

Plain English
This study looked at 139 patients with chronic myeloid leukemia who were treated with the drug imatinib after their previous treatments had failed. Over an average follow-up period of about 16.6 years, about 65% of these patients were still alive, and around 64% did not see their disease worsen during that time. The findings highlight that patients with certain genetic markers had a poorer survival outlook, but many who stopped taking imatinib after showing a strong positive response managed to stay healthy without the treatment. Who this helps: This research benefits patients with chronic myeloid leukemia and their doctors by providing insights into effective treatment options.

Plain English
This study looked at 168 patients with chronic myeloid leukemia (CML) in Italy who switched from a brand-name version of the cancer drug imatinib to a generic version. After one year, most patients (84%) maintained their best response to the drug, with only a small number experiencing changes in their condition. While 20% reported new or worsening side effects, most were able to continue with the generic medication without needing to return to the brand-name version. Who this helps: This benefits CML patients who are seeking more affordable treatment options.

Plain English
This study looked at how older patients with acute myeloid leukemia (AML) responded to two treatments called azacitidine (AZA) and decitabine (DEC). It found that the average survival for these patients was about 8 months, with AZA patients living an average of 8.8 months and DEC patients about 6.3 months. Key factors for better survival included being free from the need for blood transfusions during treatment, achieving a strong initial response to the drugs, and having higher baseline hemoglobin levels. Who this helps: This research benefits doctors treating elderly AML patients, as it provides important insights into factors affecting treatment success and survival.

Plain English
This research focused on a rare combination of two genetic mutations, BCR-ABL1 and NPM1, found in certain blood cancers, particularly acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The findings show that these mutations can affect how the disease develops and how it should be treated; for instance, BCR-ABL1 often requires a different treatment approach than NPM1 alone. Understanding these combinations helps doctors make better treatment decisions and improve patient outcomes. Who this helps: This helps patients with blood cancers and their doctors in choosing effective treatments.

Plain English
This study followed 459 patients with chronic myeloid leukemia (CML) who were treated with imatinib for an average of just over 10 years. The results showed that 77.1% of patients were still alive after ten years, with only 7.8% dying from CML and 16% dying from other causes. This matters because it demonstrates that imatinib is a long-lasting and effective treatment for CML without significant serious side effects. Who this helps: This helps patients with chronic myeloid leukemia and their doctors.

Plain English
This study focused on elderly patients over 60 years old who were newly diagnosed with chronic myeloid leukemia (CML) and treated with a medication called imatinib for at least two years. The researchers found that 27.2% of these patients developed a serious type of late anemia, with 31.8% of these requiring blood transfusions. This matters because untreated late anemia was linked to worse survival outcomes for these patients, but treating it with a medication called EPO showed promising results in all treated cases. Who this helps: This helps elderly patients with CML and their doctors by highlighting a common complication and potential treatment.

Plain English
This study looked at factors that help chronic myeloid leukemia (CML) patients achieve a stable deep molecular response (known as MR4.5) while being treated with imatinib. Out of 208 patients followed over seven years, 34.6% reached this stable response, typically after 5.4 years of treatment. Key factors linked to achieving MR4.5 included being female, being younger (average age of 56.4 vs. 58.6), having a specific genetic type of the disease, and showing early signs of a good response to treatment. Who this helps: Patients with chronic myeloid leukemia.

Plain English
This study explored how to treat children and teenagers with acute promyelocytic leukemia (APL) by using less of a harmful chemotherapy drug while still achieving good cure rates. Researchers treated 258 patients, and found that 97% reached remission, with a five-year survival rate of about 94.6%. This is significant because it shows that kids can be treated effectively without exposing them to high doses of toxic drugs. Who this helps: This helps pediatric patients with APL and their doctors.

Plain English
This study looked at how age affects the treatment outcomes of patients with chronic myeloid leukemia (CML) who were given imatinib, a common medication. The researchers found that middle-aged adults (ages 45 to 65) had better responses to treatment, with 88.9% achieving a complete cytogenetic response compared to 65.6% in young adults (ages 20 to 45) and 62.2% in elderly patients (65 and older). Although elderly patients had more deaths (16.2% compared to 3.2% in young adults), most of these deaths were not caused by CML, highlighting that age at diagnosis can significantly impact treatment outcomes. Who this helps: This research benefits doctors and healthcare providers in tailoring treatment plans and monitoring for CML patients based on their age.

Plain English
This study looked at the effectiveness of prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for patients with acute promyelocytic leukemia (APL) who had previously relapsed after initial treatment. Out of 22 patients, 20 (90%) achieved a complete remission after two treatment cycles, and after a median follow-up of nearly 5 years, 85% were still alive, with 74% remaining free of disease. This research shows that extended ATRA-ATO therapy can significantly improve outcomes for relapsed APL patients, especially those who initially responded well to treatment. Who this helps: This benefits patients with relapsed acute promyelocytic leukemia.

Plain English
This study looked at how many patients with chronic myeloid leukemia (CML) would have been excluded from two major clinical trials, Dasision and ENESTnd, based on specific health criteria. Of 207 patients treated with Imatinib, 36 (17.4%) would have been excluded from the Dasision trial and 47 (22.7%) from the ENESTnd trial, mostly due to age and other health issues. This is important because it shows that trial results may not apply well to older patients or those with additional health problems, suggesting a need for more careful consideration when using trial findings in real-world treatment settings. Who this helps: Patients with chronic myeloid leukemia, especially older ones or those with other health conditions, benefit from this understanding.

Plain English
This study looked at the significance of a protein called CD15 in patients with acute myeloid leukemia (AML) and its impact on achieving complete remission after treatment. Out of 460 patients studied, 42% tested positive for CD15, and overall, 72.6% achieved complete remission; however, 17.8% did not respond to treatment, and 9.6% died during the initial therapy phase. The findings suggest that knowing whether a patient is CD15 positive can help doctors better predict treatment outcomes, particularly in younger patients and those with specific genetic factors. Who this helps: Patients with acute myeloid leukemia and their doctors.

Plain English
This study looked at 23 patients with chronic myeloid leukemia (CML) who stopped taking alpha-interferon treatment after achieving stable complete molecular response for a long time. After about 12.5 months after stopping the treatment, one patient faced a serious complication, but most patients remained healthy without the treatment; 18 of them stayed off therapy for over 10 years, and some even showed little to no signs of the cancer returning. This matters because it suggests that some patients can safely discontinue interferon treatment without a high risk of the leukemia coming back. Who this helps: This helps CML patients who may be considering stopping their interferon treatment.

Plain English
This study examined the long-term success of treating 35 children and adolescents with chronic myeloid leukaemia (CML) without using stem cell transplants. The research found that after 10 years, about 73% of patients who received standard treatment (like interferon and tyrosine kinase inhibitors) survived, which was similar to the 72% survival rate for those who underwent stem cell transplants. It was also noted that those diagnosed after 1999 had a much higher survival rate of 100% due to improved treatments and monitoring. Who this helps: This research benefits young patients with CML and their doctors by showing effective treatment options outside of stem cell transplants.

Plain English
This study looked at the long-term effects of a high dose of imatinib, a medication for chronic myeloid leukaemia, in children and teenagers under 18 years old. Researchers followed 47 patients, who had a median age of nearly 12 years, and found that 91.5% achieved a complete response to the treatment within six months. After an average of over four years, all patients were still alive, showing that high-dose imatinib is an effective long-term treatment for this type of leukaemia in young patients. Who this helps: This benefits children and adolescents diagnosed with chronic myeloid leukaemia.

Plain English
This study looked at how the presence of a protein called CD34 on certain leukemia cells affects the outcomes for patients with acute promyelocytic leukemia (APL). Researchers analyzed data from 114 APL patients and found that those with CD34 expression had worse prognoses: for example, 66% were at high risk of relapse compared to only 17% without CD34 expression, and overall survival dropped to 60% from 95% in those without the marker. These findings show that CD34 can help identify which APL patients might face more severe challenges, and further research could improve treatment options for these individuals. Who this helps: This helps patients with acute promyelocytic leukemia and their doctors by providing critical information for treatment planning.

Plain English
This study focused on patients with chronic myelogenous leukemia (CML) being treated with imatinib, looking at how quickly they could eliminate certain cancer markers in their blood. After three months of treatment, 76% of the 182 patients showed significant improvement, while 24% still had the cancer markers, which indicated a poorer response. Those who cleared the markers early had a much better outlook, with a 97% survival rate after five years compared to only 92% for those who did not clear them. Who this helps: This research benefits patients with chronic myelogenous leukemia by identifying those who are likely to respond well to treatment early on.

Plain English
This study looked at how body weight, measured by body mass index (BMI), affects the treatment response in patients with chronic myeloid leukemia (CML) who are given certain therapies. It found that heavier patients (BMI over 25) taking imatinib took longer to show a complete response to the treatment—6.8 months compared to 3.3 months for lighter patients—and had a lower success rate in achieving a major molecular response (58% versus 77%). This matters because understanding the impact of weight on treatment effectiveness can help doctors make better decisions for managing CML. Who this helps: This helps patients with chronic myeloid leukemia and their doctors.